Article Text

Download PDFPDF
110 PROMPT: phase II trial of maintenance pembrolizumab following weekly paclitaxel for recurrent ovarian, fallopian tube or peritoneal cancer
  1. Tami Grunewald1,
  2. Rowan Miller2,
  3. Laura Tookman1,
  4. Iain Mcneish3,
  5. Rene Roux4,
  6. Laura Farrelly5,
  7. Amanda Feeney5,
  8. Anne-Marie Hacker5,
  9. Laura Hughes5,
  10. Rupali Arora6,
  11. Sergio Quezada7,
  12. Nicholas Counsell5 and
  13. Jonathan Ledermann7
  1. 1Imperial College Healthcare NHS Trust, London, UK
  2. 2Barts Health NHS Trust, London, UK
  3. 3Department of Surgery and Cancer, Imperial College, London, UK
  4. 4Oxford University Hospitals NHS Foundation Trust, Oxford, UK
  5. 5Cancer Research UK and University College London Cancer Trials Centre, London, UK
  6. 6University College London Hospitals NHS Foundation Trust, London, UK
  7. 7University College London Cancer Institute, London, UK


Introduction/Background Most women with advanced ovarian cancer eventually develop platinum-resistant disease which has a poor outcome. Median progression-free survival (PFS) is around 3–4 months and overall survival (OS) approximately 12 months. We explored the addition of maintenance pembrolizumab to extend PFS in patients who do not progress on weekly paclitaxel.

Methodology Patients were enrolled in a phase II single-arm study with response or stable disease after at least 4 cycles of paclitaxel. They were treated with pembrolizumab 200mg IV every 21 days until progression, unacceptable toxicity, patient or clinician decision. Primary endpoint was 6-month PFS rate with a target rate of 65%; <40% would be of no further interest (N=28). Secondary endpoints included OS, disease response (RECIST v1.1), toxicity and compliance.

Results Twenty evaluable patients with high grade serous carcinoma were enrolled. Median age 61 years (41–78), ECOG 0/1 50%/50%. 85% of patients had stage III/IV at diagnosis and had received a median of 5.5 prior cycles (4–17) weekly paclitaxel, with 35% achieving partial response and 65% stable disease. A median of 3.5 cycles (2–18) of pembrolizumab were given; 19 patients (95%) stopped due to progression and 1 discontinued due to a treatment-related adverse event (TRAE) of hepatitis. Two (10%) patients had 3 grade 3 TRAEs: rash; hepatitis and diarrhoea. There were no grade 4/5 TRAEs. After a median follow-up of 16.5 months, median PFS from the start of pembrolizumab was 2.0 months (95%CI: 1.8–3.6) and median OS was 9.8 months (95%CI: 6.2–20.7). As the 6-month PFS rate was 5.0% (95%CI: 0.3–20.5) the trial stopped early due to futility.

Conclusion Maintenance pembrolizumab did not improve PFS in patients with platinum-resistant ovarian cancer with non-progressive disease after paclitaxel. Planned translational research on diagnostic, tissue biopsies and blood samples is crucial to understand why most patients with ovarian cancer do not benefit from immune checkpoint inhibitors.

Disclosures Please see attached signed COI forms.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.